Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study
Joseph Mıkhael(Translational Genomics Research Institute), S. Vincent Rajkumar(WinnMed), Kurt R. Oettel(Gundersen Health System), Abraham S. Kanate(HonorHealth), Suzanne R. Hayman, Brendan M. Weiss(Heidelberg University), Judi Manola(Dana-Farber Cancer Institute), Sagar Lonial(Emory University)
Cited by 0
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
|Blood|2010|866
Multiple myeloma
|Blood|2008|852